Physician profile
Dmitry Blumenkrants
NPI 1235428657
$7,865.27
in general payments reported to CMS, 2019-2025
31 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,989 · 2020: $142 · 2022: $511 · 2023: $1,823 · 2024: $2,368 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,263 · Travel and Lodging: $1,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,263.48 |
| Travel and Lodging | $1,960.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,540.09 | 2019-2025 | Watchman Flx |
| Ge Healthcare | $1,496.65 | 2024-2025 | |
| Edwards Lifesciences Corporation | $1,489.04 | 2019-2025 | Pascal, Sapien 3 Ultra Resilia, Evoque |
| Heartflow, INC. | $699.82 | 2020-2025 | Ffrct |
| Novartis Pharmaceuticals Corporation | $346.62 | 2019-2025 | |
| Pfizer INC. | $310.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $275.18 | 2019-2025 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $235.15 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.55 | 2020-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $191.98 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $136.39 | 2024-2025 | Ozempic, Wegovy |
| Regeneron Healthcare Solutions, INC. | $130.81 | 2019-2025 | Evkeeza |
| Amgen INC. | $119.89 | 2019-2024 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $110.32 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $91.70 | 2023-2025 | Verquvo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $63.48 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $52.30 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $50.72 | 2023-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $49.88 | 2024 | Mitraclip |
| Actelion Pharmaceuticals US, INC. | $43.86 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Alnylam Pharmaceuticals INC. | $41.53 | 2024 | Onpattro |
| Lantheus Medical Imaging, INC. | $41.20 | 2019-2024 | |
| Integra Lifesciences Corporation | $24.15 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Atricure, INC. | $23.16 | 2025 | Synergy Ablation System |
| Ekos Corporation | $19.52 | 2019 | |
| Bridgebio Pharma, INC. | $18.70 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $15.23 | 2023 | Assure Wcd |
| Amarin Pharma, INC. | $14.72 | 2020 | |
| Chiesi USA, INC. | $13.39 | 2023 | Cleviprex, Kengreal |
| Lexicon Pharmaceuticals, INC. | $13.18 | 2024 | |
| Altathera Pharmaceuticals LLC | $12.83 | 2023 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitry Blumenkrants listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.